From computational molecular design to GMP-certified manufacturing at scale, our integrated platform bridges the gap between discovery and delivery through rigorous science and proprietary technology.
Our proprietary antibody platform leverages advanced computational biology and high-throughput screening to engineer monoclonal antibodies with superior binding affinity, stability, and manufacturability.
Optimized for high-yield, stable expression of complex glycoproteins with titers exceeding 8 g/L in fed-batch culture.
Machine learning models screen 4,200+ candidates in 72 hours, predicting immunogenicity and developability scores.
Fully Halal-compliant upstream and downstream processing, meeting both SFDA and global regulatory standards.
A comprehensive view of our clinical programs including target mechanisms, therapeutic areas, and modalities. Hover over any candidate for full clinical data.
End-to-end capabilities enabling rapid development and scalable manufacturing.
Proprietary CHO cell platforms optimized for high-yield, stable expression of complex proteins and monoclonal antibodies. Industry-leading titers with robust scalability characteristics.
End-to-end process development from upstream perfusion to downstream purification, designed for scalability and regulatory compliance. Continuous-flow microfluidics for seamless bench-to-commercial transition.
Comprehensive suite of analytical methods for product characterization, stability testing, and release. Real-time PAT analytics with HPLC and mass spectrometry ensuring quality and safety at every step.
Leverage our proprietary platforms and sovereign manufacturing infrastructure to accelerate your biopharmaceutical programs.